PB 97 of 2022
National Health (October 2022 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2022
National Health Act 1953
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care make this determination under subsection 99ADHB(6) of the National Health Act 1953.
Dated 29 September 2022
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
1 Name of Determination
(1) This instrument is the National Health (October 2022 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2022.
(2) This instrument may also be cited as PB 97 of 2022.
2 Commencement
This instrument commences on 1 October 2022.
3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act,
In this instrument:
Act means the National Health Act 1953.
4 Authority
This instrument is made under subsection 99ADHB(6) of the Act.
5 Brand of pharmaceutical item with approved ex-manufacturer price not reduced
I determine under subsection 99ADHB(6) of the Act that, for the purposes of subsection 99ADHB(2), the approved ex-manufacturer price that comes into force on 1 October 2022 of the brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is to be worked out using a reduction of 6%.
Schedule 1— Brand of pharmaceutical item with approved ex-manufacturer price reduced by 6%
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand |
1 | Sacubitril with valsartan | Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg | Oral | Entresto |
2 | Sacubitril with valsartan | Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg | Oral | Entresto |